ArticleCells2022
The Landscape of Tumor-Infiltrating Immune Cells in Feline Mammary Carcinoma: Pathological and Clinical Implications.
Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Feline Mammary Carcinoma as a Comparative Model of Human Breast Cancer: An Integrative Review.Cancers · 2026Article
- Review
- Virus-like particles in cancer immunotherapy: bridging human and veterinary medicine through one health.Journal of nanobiotechnology · 2026Review
- Grade III canine and feline mammary carcinomas are associated with an immunosuppressed, vascularized and proliferative microenvironment.BMC veterinary research · 2026Article
- Serum programmed death ligand 2 is elevated in cats with mammary carcinoma.Scientific reports · 2026Article
- Inside the Tumor: Decoding the Feline Mammary Tumor Microenvironment and Its Prognostic Value-A Review.Veterinary sciences · 2025Review
- Feline Mammary Tumors: A Comprehensive Review of Histological Classification Schemes, Grading Systems, and Prognostic Factors.Veterinary sciences · 2025Review
- PD-1, PD-L1, and PD-L2 Expression as Predictive Markers in Rare Feline Mammary Tumors.Veterinary sciences · 2025Article
- Do Pre-Treatment Biopsy Characteristics Predict Early Tumour Progression in Feline Diffuse Large B Cell Nasal Lymphoma Treated With Radiotherapy?Veterinary and comparative oncology · 2025Article
- Tumor-Infiltrating Lymphocytes and Neutrophils and Their Location in Canine Mammary Neoplasms with a Solid Arrangement: A Prognostic Factor?Animals : an open access journal from MDPI · 2025Article
- Insights from veterinary models for advancing oncolytic virotherapy through comparative oncology.Frontiers in molecular biosciences · 2025Review
- Level of Necrosis in Feline Mammary Tumors: How to Quantify, Why and for What Purpose?Animals : an open access journal from MDPI · 2024Article
- Tumor Immune Microenvironment and Its Clinicopathological and Prognostic Associations in Canine Splenic Hemangiosarcoma.Animals : an open access journal from MDPI · 2024Article
- Comparative pharmacokinetics of free doxorubicin and a liposomal formulation in cats following intravenous administration.Frontiers in veterinary science · 2024Article
- Adipocyte-Derived Adipokines and Other Obesity-Associated Molecules in Feline Mammary Cancer.Biomedicines · 2023Review
- Development of anti-feline PD-1 antibody and its functional analysis.Scientific reports · 2023Article
- LOCATOR: feature extraction and spatial analysis of the cancer tissue microenvironment using mass cytometry imaging technologies.Bioinformatics advances · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Feline mammary carcinoma (FMC) shares key molecular and clinicopathological features with human breast cancer. We have herein studied the inflammatory infiltrate of FMC in order to uncover potential therapeutic targets and prognostic markers. To this end, the expression of different markers (CD3, CD4, CD8, CD20, CD56, FoxP3, CD68 and CD163) was analyzed in total, stromal (s) and intratumoral (i) tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs), in 73 feline mammary carcinomas. The results revealed that higher percentages of sCD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.